التفاصيل البيبلوغرافية
| العنوان: |
Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data. |
| المؤلفون: |
Jimenez-Zepeda, Victor H., Reece, Donna, Rigo, Rodrigo, Gogna, Priyanka, Kong, Shiying, Hu, Xun Yang, Chapani, Parv, Cheung, Winson Y., Brenner, Darren R., Plante, Richard, Shi, Kun, Husain, Asad, Ammann, Eric, Tankala, Dipti, Boyne, Devon J. |
| المصدر: |
Leukemia & Lymphoma; Jan2023, Vol. 64 Issue 1, p256-258, 3p |
| مصطلحات موضوعية: |
AMYLOIDOSIS, CARDIAC amyloidosis, AMYLOID, IMMUNOGLOBULIN light chains, ALGORITHMS |
| مستخلص: |
Amyloid light chain (AL) amyloidosis is a rare plasma cell disease in which AL protein deposits form throughout the body, with the heart, and kidney being the most commonly affected organs [[1]]. Quock et al. previously developed an algorithm for AL amyloidosis whereby individuals with general amyloidosis ICD codes were flagged as having AL amyloidosis if they received one or more guideline concordant therapies [[3]]. Individuals were flagged as having AL amyloidosis if they had one inpatient or two outpatient amyloidosis ICD codes and had received any one of the following AL amyloidosis therapies on or after the date of the earliest amyloidosis ICD code: cyclophosphamide, carfilzomib, bortezomib, bendamustine, daratumumab, lenalidomide, melphalan, ixazomib, pomalidomide, and thalidomide. [Extracted from the article] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
